Navigation Links
AutoGenomics CYP 2C19 Test Used in Study to Personalize Clopidogrel (Plavix) Dosing in Patients

CARLSBAD, Calif., Jan. 22 /PRNewswire/ -- AutoGenomics, a leader in providing automated molecular testing solutions announced today that its CYP450 2C19 assay was used in a study to demonstrate the value of genetic variants in dosing of the antiplatelet agent, Plavix.

Plavix, commonly known as Clopidogrel, is an anti-platelet agent used in the treatment for coronary artery disease, peripheral vascular disease and cerebrovascular disease. To realize the antiplatelet effect, Clopidogrel requires biotransformation to an active metabolite by cytochrome P-450 enzymes.

"Personalizing Clopidogrel dosing using pharmacogenetics may be an effective method of rationalizing treatment. In a recent study we used the AutoGenomics 2C19 test to screen for polymorphisms associated with a reduced response to the drug" said Dr. Mark Webster, Director of Cardiac Catheterization at the Auckland City Hospital. His co-investigator Dr. Patrick Gladding said that "other studies have shown that patients treated with Clopidogrel with a reduced function CYP C219 genetic variant had lower levels of the active metabolite resulting in a reduced antiplatelet response to the drug and a three-fold risk of stent thrombosis."

"We are pleased that Dr. Webster and Dr. Gladding have taken a pioneering role in assessing the role of genetic variants in Clopidogrel dosing to ensure patient safety. The AutoGenomics platform enables the rapid testing of such CYP 450 tests including CYP 2C9, CYP 3A4 & CYP 3A5 that have been quoted in recent publications as factors that could be of interest in drug dosing" said Ramanath Vairavan, Senior Vice President at AutoGenomics. He further said "that recent studies published in the New England Journal of Medicine indicated that about 30% of the patients had at least one CYP 2C19 reduced function genetic variant". With such high incidence of these reduced functional alleles it is gratifying to note the active role that FDA is taking to re-label these drugs and help realize the promise of personalized medicine to ensure drug efficacy and patient safety".

About AutoGenomics

AutoGenomics Inc., a privately held company based in Carlsbad, CA, has developed the first automated, microarray based multiplexing diagnostic platform that can be used to assess disease signatures with novel genomic and proteomic markers in the area of genetic disorders, infectious disease, cancer and pharmacogenetics. With the discovery of genes and their link to various disease states the platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed leading to the era of personalized medicine.

SOURCE AutoGenomics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AutoGenomics Receives FDA Clearance for its INFINITI(TM) Warfarin Assay
2. AutoGenomics Receives a Key European Patent for HPV Detection
3. AutoGenomics INFINITI Analyzer Receives Artistic Design Award
4. AutoGenomics, Inc. Files Registration Statement for Initial Public Offering
5. Penn study finds pro-death proteins required to regulate healthy immune function
6. New study shows promise in reducing surgical risks associated with surgical bleeding
7. Study, meta-analysis examine factors associated with death from heatstroke
8. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
9. Study says COPD testing is not measuring up
10. Preclinical study suggests organ-transplant drug may aid in lupus fight
11. Ability to cope with stress can increase good cholesterol in older white men, study finds
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
Breaking Medicine Technology: